The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.e

Pneumocystis jiroveci pneumonia

Has received experimental support (PMID 25733518)

Publications

Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rheumatology (Oxford, England) 2018 06 01;57;997-1001 — 2018 06 01 — 997-1001

Alexandre K, Ingen-Housz-Oro S, Versini M, Sailler L, Benhamou Y

Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: Report of 11 cases and review of the literature.

European journal of internal medicine 2018 04;50;e23-e24 — 2018 04 — e23-e24

Lee J, Lee JG, Kim S, Song SH, Kim BS, Kim HO, Kim MS, Kim SI, Kim YS, Huh KH

The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2016 06;31;1013-21 — 2016 06 — 1013-21

Reynaud Q, Killian M, Robles A, Mounsef F, Camdessanché JP, Mariat C, Cathébras P

[Review of the current use of rituximab during 4 years in a French university hospital].

La Revue de medecine interne 2015 Dec;36;800-12 — 2015 Dec — 800-12

Jiang X, Mei X, Feng D, Wang X

Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.

PloS one 2015;10;e0122171 — 2015 — e0122171

Jiang XQ, Fang L, Mei XD, Wang XJ, Bao MH

Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma after Rituximab-containing regimen: two cases of report and literature review.

Journal of thoracic disease 2013 Aug;5;E162-6 — 2013 Aug — E162-6

Besada E, Nossent JC

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Clinical rheumatology 2013 Nov;32;1677-81 — 2013 Nov — 1677-81

Martin-Garrido I, Carmona EM, Specks U, Limper AH

Pneumocystis pneumonia in patients treated with rituximab.

Chest 2013 Jul;144;258-265 — 2013 Jul — 258-265

Tsai MJ, Chou CW, Lin FC, Chang SC

Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy.

Lupus 2012 Jul;21;914-8 — 2012 Jul — 914-8

Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH

Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.

Annals of hematology 2011 Oct;90;1145-51 — 2011 Oct — 1145-51

Lim KH, Yoon HI, Kang YA, Lee KW, Kim JH, Bang SM, Lee JH, Lee CT, Lee JS

Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

The Korean journal of internal medicine 2010 Mar;25;86-92 — 2010 Mar — 86-92